期刊
CLINICAL & TRANSLATIONAL ONCOLOGY
卷 16, 期 12, 页码 1060-1066出版社
SPRINGER INTERNATIONAL PUBLISHING AG
DOI: 10.1007/s12094-014-1225-3
关键词
Androgen deprivation treatment; Castration-resistant prostate cancer; Docetaxel; Cabacitaxel; Abiraterone; Enzalutamide; Radium 223
类别
Androgen deprivation treatment is the current standard first-line treatment for metastatic prostate cancer. For several years, docetaxel was the only treatment with a proven survival benefit for castration-resistant prostate cancer (CRPC). Since docetaxel became standard of care for men with symptomatic metastatic castration-resistant prostate cancer (CRPC), three treatment virtual spaces, for treatment and drug development in CPRC, have emerged: pre-docetaxel, docetaxel combinations and post-docetaxel. Sipuleucel-T, cabazitaxel, abiraterone, enzalutamide and radium-223 have been approved in the pre- or post-docetaxel setting in metastatic CRPC during the last few years. Patients are now living longer and experiencing better quality of life. Strategies for patient selection and treatment sequencing are therefore urgently required.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据